Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992 · see citing works

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · see citing works

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623 · see citing works

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571 · see citing works

MDM2 inhibitors for cancer therapy

Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · see citing works

MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy

Kojima, K., Konopleva, M. Y., Samudio, I. J., Shikami, M., Cabreira-Hansen, M. D. G., McQueen, T. J., Ruvolo, V. R., Tsao, T., Zeng, Z., Vassilev, L. T., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0553 · Cited by 407 · see citing works

Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development

Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395 · see citing works

Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets

Schoenwaelder, S. M., Jarman, K. E., Gardiner, E. E., Hua, M., Qiao, J., White, M. J., Josefsson, E. C., Alwis, I., Ono, A., Willcox, A., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347849 · Cited by 351 · see citing works

MDM2 is a Central Node in the p53 Pathway: 12 Years and Counting

Bond, G. L., Hu, W., & Levine, A. J. (2005) · Current Cancer Drug Targets · doi:10.2174/1568009053332627 · Cited by 310 · see citing works

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models

Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283 · see citing works

Different ploidy levels of megakaryocytes generated from peripheral or cord blood CD34+ cells are correlated with different levels of platelet release

Mattia, G., Vulcano, F., Milazzo, L., et al. (2002) · Blood · doi:10.1182/blood.v99.3.888 · Cited by 245 · see citing works

Biology and Chemistry of Thrombopoietic Agents

Kuter, D. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.02.005 · Cited by 103 · see citing works

Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside

Deutsch, V. R., & Tomer, A. (2013) · British Journal of Haematology · doi:10.1111/bjh.12328 · Cited by 102 · see citing works

Role of p21Cip1/Waf1 in cell-cycle exit of endomitotic megakaryocytes

Baccini, V., Roy, L., Vitrat, N., Chagraoui, H., Sabri, S., Couedic, J. P. L., Debili, N., Wendling, F., & Vainchenker, W. (2001) · Blood · doi:10.1182/blood.v98.12.3274 · Cited by 77 · see citing works

Histone Deacetylase Inhibitors: Advancing Therapeutic Strategies in Hematological and Solid Malignancies

Ellis, L., & Пили, Р. (2010) · Pharmaceuticals · doi:10.3390/ph3082441 · Cited by 64 · see citing works

Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome

McGowan, K. A., Pang, W. W., Bhardwaj, R., Perez, M. G., Pluvinage, J. V., Glader, B. E., Malek, R. A., Mendrysa, S. M., Weissman, I. L., Park, C. Y., et al. (2011) · Blood · doi:10.1182/blood-2010-11-318584 · Cited by 63 · see citing works

High Doses of Romiplostim Induce Proliferation and Reduce Proplatelet Formation by Human Megakaryocytes

Currao, M., Balduini, C. L., & Balduini, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054723 · Cited by 59 · see citing works

Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation

Iancu‐Rubin, C., Gajzer, D. C., Mosoyan, G., Feller, F. M., Mascarenhas, J. O., & Hoffman, R. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.02.004 · Cited by 55 · see citing works

SCL-mediated regulation of the cell-cycle regulator p21 is critical for murine megakaryopoiesis

Chagraoui, H., Kassouf, M. T., Banerjee, S., Goardon, N., Clark, K., Atzberger, A., Pearce, A. C., Skoda, R. C., Ferguson, D. J. P., Watson, S. P., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328765 · Cited by 46 · see citing works

Tumor Suppressor Protein p53 Regulates Megakaryocytic Polyploidization and Apoptosis

Fuhrken, P. G., Apostolidis, P. A., Lindsey, S. C., Miller, W. M., & Papoutsakis, E. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m801923200 · Cited by 45 · see citing works

Role of tumor suppressor p53 in megakaryopoiesis and platelet function

Apostolidis, P. A., Woulfe, D. S., Chavez, M., Miller, W. M., & Papoutsakis, E. T. (2011) · Experimental Hematology · doi:10.1016/j.exphem.2011.10.006 · Cited by 41 · see citing works

Proposed megakaryocytic regulon of p53: the genes engaged to control cell cycle and apoptosis during megakaryocytic differentiation

Apostolidis, P. A., Lindsey, S. C., Miller, W. M., & Papoutsakis, E. T. (2012) · Physiological Genomics · doi:10.1152/physiolgenomics.00028.2012 · Cited by 36 · see citing works

Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production

Iancu‐Rubin, C., Gajzer, D. C., Tripodi, J., et al. (2011) · Blood · doi:10.1182/blood-2010-09-305540 · Cited by 35 · see citing works

Evaluation of platelet turnover by flow cytometry

Salvagno, G. L., Montagnana, M., Degan, M., et al. (2006) · Platelets · doi:10.1080/09537100500437851 · Cited by 34 · see citing works

Two colour analysis of reticulated platelets

Robinson, M. S. C., Mackie, I. J., Machin, S. J., et al. (2000) · Clinical & Laboratory Haematology · doi:10.1046/j.1365-2257.2000.00117.x · Cited by 33 · see citing works

A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112, A First In Class p53-MDM2 Antagonist, In Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocytic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)

Andreeff, M., Kojima, K., Padmanabhan, S., STRAIR, R. K., Kirschbaum, M. H., Maslak, P. G., Hillmen, P., O'Brien, S. M., Samaniego, F., Borthakur, G. M., et al. (2010) · Blood · doi:10.1182/blood.v116.21.657.657 · Cited by 29 · see citing works

Results of the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist, in Acute Leukemia

Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2012) · Blood · doi:10.1182/blood.v120.21.675.675 · Cited by 20 · see citing works

Modulation of MDM2/p53 and cyclin-activating kinase during the megakaryocyte differentiation of human erythroleukemia cells

Datta, N. S., & Long, M. W. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00780-9 · Cited by 18 · see citing works

Vertical Pathway Targeting in Cancer Therapy

Shahbazian, D., Sznol, J. A., & Kluger, H. M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00001-4 · Cited by 17 · see citing works

Neoadjuvant MDM2 antagonist RG7112 for well-differentiated and dedifferentiated liposarcomas (WD/DD LPS): A pharmacodynamic (PD) biomarker study.

Ray-Coquard, I., Blay, J., Italiano, A., Cesne, A. L., Penel, N., Zhi, J., Beryozkina, A., Heil, F., Rueger, R., NICHOLS, G. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.10007b · Cited by 11 · see citing works

Pharmacokinetics (PK) and pharmacodynamics (PD) of RG7112, an oral murine double minute 2 (MDM2) antagonist, in patients with leukemias and solid tumors.

Beryozkina, A., NICHOLS, G. L., Reckner, M., Vassilev, L. T., Rueger, R., Jukofsky, L., Middleton, S., Andreeff, M., Padmanabhan, S., STRAIR, R. K., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3039 · Cited by 9 · see citing works

HDACI-induced thrombocytopenia is caused by its unexpected target

Kitamura, T., & Inoue, D. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.07.001 · Cited by 3 · see citing works

Small-Molecule Inhibitors of the MDM2–p53 Protein–Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment

Zhao, Y., Aguilar, A., Bernard, D., & Wang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501092z · Cited by 462 · see citing works

Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>

Saleh, M. N., Patel, M. R., Bauer, T. M., Goel, S., Falchook, G. S., Shapiro, G. I., Chung, K. Y., Infante, J. R., Conry, R. M., Rabinowits, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0715 · Cited by 159 · see citing works

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives

Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106 · see citing works

Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer

He, S., Ma, J., Fang, Y., Liu, Y., Wu, S., Dong, G., Wang, W., & Sheng, C. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.11.022 · Cited by 91 · see citing works

Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment

Gu, L., Zhang, H., Liu, T., Zhou, S., Du, Y., Xiong, J., Yi, S., Qu, C.-K., Fu, H., & Zhou, M. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.08.015 · Cited by 86 · see citing works

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

de Weger, V. A., de Jonge, M., Langenberg, M. H. G., Schellens, J. H. M., Lolkema, M., Varga, A., Demers, B., Thomas, K., Hsu, K., Tuffal, G., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0355-8 · Cited by 62 · see citing works

Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification

Cornillie, J., Wozniak, A., Li, H., Gebreyohannes, Y. K., Wellens, J., Hompes, D., Debiec-Rychter, M., Sciot, R., & Schöffski, P. (2020) · Clinical and Translational Oncology · doi:10.1007/s12094-019-02158-z · Cited by 56 · see citing works

P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis

Mahfoudhi, E., Lordier, L., Marty, C., Pan, J., Roy, A., Roy, L., Rameau, P., Abbes, S., Debili, N., Raslova, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7881 · Cited by 53 · see citing works

Combination therapy in a xenograft model of glioblastoma: Enhancement of the antitumor activity of temozolomide by an MDM2 antagonist

Wang, H., Cai, S., Bailey, B. J., Reza Saadatzadeh, M., Ding, J., Tonsing-Carter, E., Georgiadis, T. M., Zachary Gunter, T., Long, E. C., Minto, R. E., et al. (2017) · Journal of Neurosurgery · doi:10.3171/2016.1.jns152513 · Cited by 49 · see citing works

Initial Testing (Stage 1) of MK‐8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program

Kang, M. H., Reynolds, C. P., Kolb, E. A., Gorlick, R., Carol, H., Lock, R., Keir, S. T., Maris, J. M., Wu, J., Lyalin, D., et al. (2016) · Pediatric Blood &amp; Cancer · doi:10.1002/pbc.26064 · Cited by 36 · see citing works

Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma

Phelps, D., Bondra, K., Seum, S., Chronowski, C., Leasure, J., Kurmasheva, R. T., Middleton, S., Wang, D., Mo, X., & Houghton, P. J. (2015) · Pediatric Blood &amp; Cancer · doi:10.1002/pbc.25465 · Cited by 27 · see citing works

Therapeutic Efficacy of <i>p53</i> Restoration in <i>Mdm2</i> -Overexpressing Tumors

Li, Q., Zhang, Y., El-Naggar, A. K., Xiong, S., Yang, P., Jackson, J. G., Chau, G., & Lozano, G. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0089 · Cited by 30 · see citing works

Platelets in Pulmonary Vascular Physiology and Pathology

Kroll, M. H. (2010) · Springer eBooks · doi:10.1007/978-0-387-87429-6_24 · Cited by 3 · see citing works

A novel inhibitor of MDM2 oncogene blocks metastasis of hepatocellular carcinoma and overcomes chemoresistance

Wang, W., Hu, B., Qin, J., Cheng, J., Li, X., Rajaei, M., Fan, J., Yang, X., & Zhang, R. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.001 · Cited by 53 · see citing works

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors

Hou, H., Sun, D., & Zhang, X. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0937-4 · Cited by 232 · see citing works

circNUDT21 promotes bladder cancer progression by modulating the miR-16-1-3p/MDM2/p53 axis

Chen, L., Li, W., Li, Z., Song, Y., Zhao, J., Chen, Z., Kazobinka, G., Li, L., Xing, Y., & Hou, T. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.08.032 · Cited by 24 · see citing works